Voyager Therapeutics's Cancer Antibody Program Shows Encouraging Preclinical Action

by Vandana Singh, Benzinga Editor

November 19, 2021 8:57 AM | 1 min read | Make a Comment

Voyager Therapeutics Inc VYGR announced preclinical data from a new vectorized anti-HER2 antibody program.
Data showed that IV dosing of a proprietary AAV vector identified by the TRACER screening technology, encoding an anti-HER2 antibody payload, prevented tumor growth in animal models of brain metastases.
Peripheral administration of TRACER AAV vector resulted in the production of efficacious levels of HER2-directed antibodies for extended periods.
Related: Voyager Therapeutics Stock Soars On License Option Pact With Pfizer.
Price Action: VYGR shares are up 3.16% at $3.26 during the premarket session on the last check Friday.